{"corpus_id":10565127,"paper_sha":"c2e6dfa7197b35869a1c6132c24c57b6101ab328","doi":"10.1001/JAMA.290.16.2149","arxiv_id":null,"pmid":14570950,"pmcid":null,"mag_id":2120718661,"dblp_id":null,"acl_id":null,"title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.","year":2003,"publication_date":"2003-10-22","venue":"Journal of the American Medical Association (JAMA)","journal":{"name":"JAMA","pages":"\n          2149-58\n        ","volume":"290 16"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial","Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":52,"citation_count":2651,"influential_citation_count":93,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Administration, Oral","mj":false,"ui":"D000284"},{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Aged, 80 and over","mj":false,"ui":"D000369"},{"d":"Antineoplastic Agents","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D000970"},{"d":"Carcinoma, Non-Small-Cell Lung","mj":false,"qs":[{"q":"diagnostic imaging","mj":false,"ui":"Q000000981"},{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"physiopathology","mj":false,"ui":"Q000503"}],"ui":"D002289"},{"d":"Double-Blind Method","mj":false,"ui":"D004311"},{"d":"Enzyme Inhibitors","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D004791"},{"d":"ErbB Receptors","mj":false,"qs":[{"q":"antagonists & inhibitors","mj":true,"ui":"Q000037"}],"ui":"D066246"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Gefitinib","mj":false,"ui":"D000077156"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Lung Neoplasms","mj":false,"qs":[{"q":"diagnostic imaging","mj":false,"ui":"Q000000981"},{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"physiopathology","mj":false,"ui":"Q000503"}],"ui":"D008175"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Quinazolines","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D011799"},{"d":"Radiography","mj":false,"ui":"D011859"},{"d":"Survival Analysis","mj":false,"ui":"D016019"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"}],"chemicals":[{"n":"Antineoplastic Agents","ui":"D000970","reg":"0"},{"n":"Enzyme Inhibitors","ui":"D004791","reg":"0"},{"n":"Quinazolines","ui":"D011799","reg":"0"},{"n":"ErbB Receptors","ui":"D066246","reg":"EC 2.7.10.1"},{"n":"Gefitinib","ui":"D000077156","reg":"S65743JHBS"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://jamanetwork.com/journals/jama/articlepdf/197532/JOC31026.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/c2e6dfa7197b35869a1c6132c24c57b6101ab328","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"CONTEXT: More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a fraction of patients with NSCLC progressing after chemotherapy experience both a decrease in lung cancer symptoms and radiographic tumor shrinkages with gefitinib. OBJECTIVE: To assess differences in symptomatic and radiographic response among patients with NSCLC receiving 250-mg and 500-mg daily doses of gefitinib. DESIGN, SETTING, AND PATIENTS: Double-blind, randomized phase 2 trial conducted from November 2000 to April 2001 in 30 US academic and community oncology centers. Patients (N = 221) had either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens. INTERVENTION: Daily oral gefitinib, either 500 mg (administered as two 250-mg gefitinib tablets) or 250 mg (administered as one 250-mg gefitinib tablet and 1 matching placebo). MAIN OUTCOME MEASURES: Improvement of NSCLC symptoms (2-point or greater increase in score on the summed lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung [FACT-L] instrument) and tumor regression (>50% decrease in lesion size on imaging studies). RESULTS: Of 221 patients enrolled, 216 received gefitinib as randomized. Symptoms of NSCLC improved in 43% (95% confidence interval [CI], 33%-53%) of patients receiving 250 mg of gefitinib and in 35% (95% CI, 26%-45%) of patients receiving 500 mg. These benefits were observed within 3 weeks in 75% of patients. Partial radiographic responses occurred in 12% (95% CI, 6%-20%) of individuals receiving 250 mg of gefitinib and in 9% (95% CI, 4%-16%) of those receiving 500 mg. Symptoms improved in 96% of patients with partial radiographic responses. The overall survival at 1 year was 25%. There were no significant differences between the 250-mg and 500-mg doses in rates of symptom improvement (P =.26), radiographic tumor regression (P =.51), and projected 1-year survival (P =.54). The 500-mg dose was associated more frequently with transient acne-like rash (P =.04) and diarrhea (P =.006). CONCLUSIONS: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.","claims":[{"public_id":"cl_c3ccc2313372b5a7d18905c4af7de15f","status":"active","text":"Gefitinib improved disease-related symptoms in patients with advanced non-small cell lung cancer persisting after chemotherapy.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c3ccc2313372b5a7d18905c4af7de15f"},{"public_id":"cl_385381b5e58e77590ffebbbe8a232f76","status":"active","text":"Gefitinib induced partial radiographic tumor regressions in a subset of patients with advanced non-small cell lung cancer.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_385381b5e58e77590ffebbbe8a232f76"},{"public_id":"cl_c70fd25ea4012d0e92c100775f151f62","status":"active","text":"Most symptomatic benefits appeared within 3 weeks, and symptom improvement was seen in nearly all patients with partial radiographic responses.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c70fd25ea4012d0e92c100775f151f62"},{"public_id":"cl_d9ab9821caf7992f910a135a8a377f21","status":"active","text":"No significant differences were observed between the 250-mg and 500-mg gefitinib doses in symptom improvement, tumor regression, or projected 1-year survival.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_d9ab9821caf7992f910a135a8a377f21"},{"public_id":"cl_f357cbb949a94515721f7044d95680ef","status":"active","text":"The 500-mg gefitinib dose caused transient acne-like rash and diarrhea more frequently than the 250-mg dose.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_f357cbb949a94515721f7044d95680ef"}],"concepts":[{"public_id":"co_03bc8db420e3b0b4cc590ab3161004fd","status":"active","name":"projected 1-year survival","description":"The estimated survival probability at one year after treatment.","types":["outcome"],"aliases":["overall survival at 1 year"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_03bc8db420e3b0b4cc590ab3161004fd"},{"public_id":"co_14dbff488680166233197f67a900b84b","status":"active","name":"non-small cell lung cancer","description":"A lung cancer subtype studied in patients with advanced disease.","types":["condition"],"aliases":["NSCLC"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_14dbff488680166233197f67a900b84b"},{"public_id":"co_23506338cefffcec96e451bcdec57e91","status":"active","name":"symptom improvement","description":"An increase in lung cancer symptom scores measured with the FACT-L lung cancer subscale.","types":["outcome"],"aliases":["improvement of NSCLC symptoms"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_23506338cefffcec96e451bcdec57e91"},{"public_id":"co_2bda614e9af1a42f3e39ac916c02ccd1","status":"active","name":"radiographic tumor regression","description":"A decrease in lesion size on imaging studies indicating tumor shrinkage.","types":["outcome"],"aliases":["tumor regression","partial radiographic response"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2bda614e9af1a42f3e39ac916c02ccd1"},{"public_id":"co_2eadffea10632d71def882ebadbebe72","status":"active","name":"250-mg gefitinib dose","description":"The lower daily oral gefitinib dose tested in the randomized trial.","types":["intervention dose"],"aliases":["250 mg"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2eadffea10632d71def882ebadbebe72"},{"public_id":"co_31f64114a66927bedb27f15434a6fc04","status":"active","name":"acne-like rash","description":"A transient skin adverse event reported with gefitinib treatment.","types":["adverse event"],"aliases":["transient acne-like rash"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_31f64114a66927bedb27f15434a6fc04"},{"public_id":"co_3f73ea690a19072f47d43023dd5b67aa","status":"active","name":"gefitinib","description":"An oral epidermal growth factor receptor tyrosine kinase inhibitor used as the study drug.","types":["drug","therapy"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3f73ea690a19072f47d43023dd5b67aa"},{"public_id":"co_6b2252d0ef498cc16b1435067231d5b0","status":"active","name":"chemotherapy","description":"Prior systemic cancer treatment that patients had already received before enrollment.","types":["treatment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6b2252d0ef498cc16b1435067231d5b0"},{"public_id":"co_7355479b825293af549dd7d688e3cd03","status":"active","name":"epidermal growth factor receptor tyrosine kinase inhibitor","description":"A class of drugs that block signaling through the epidermal growth factor receptor.","types":["drug class","mechanism"],"aliases":["EGFR tyrosine kinase inhibitor","EGFR-TKI"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7355479b825293af549dd7d688e3cd03"},{"public_id":"co_80433368bdb51844e2f0c7b4b44600f5","status":"active","name":"diarrhea","description":"A gastrointestinal adverse event reported with gefitinib treatment.","types":["adverse event"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_80433368bdb51844e2f0c7b4b44600f5"},{"public_id":"co_c8010c00975759f5055af9f2b9447799","status":"active","name":"3 weeks","description":"The time window within which most symptom benefits were observed.","types":["time interval"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c8010c00975759f5055af9f2b9447799"},{"public_id":"co_e76c6e58565611c4ec460101f3b24694","status":"active","name":"500-mg gefitinib dose","description":"The higher daily oral gefitinib dose tested in the randomized trial.","types":["intervention dose"],"aliases":["500 mg"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e76c6e58565611c4ec460101f3b24694"}],"external_ids":{"DOI":"10.1001/JAMA.290.16.2149","ArXiv":null,"PubMed":14570950,"PubMedCentral":null,"MAG":2120718661,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://jamanetwork.com/journals/jama/articlepdf/197532/JOC31026.pdf","landing_url":"https://www.semanticscholar.org/paper/c2e6dfa7197b35869a1c6132c24c57b6101ab328","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631620,"paper_uid":"b9241143-4d5d-4ce6-80a2-8464567ad491","canonical_identity":{"paper_id":631620,"paper_uid":"b9241143-4d5d-4ce6-80a2-8464567ad491","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/10565127"}